Stanford Peng, M.D., Ph.D.

Stanford joined Frazier Life Sciences as a Venture Partner in 2025.

Stanford is a Venture Partner at Frazier Life Sciences, where he is focused on company creation opportunities. He is a physician-scientist R&D executive with over 25 years of drug development and basic biomedical research experience in multiple settings, spanning newco startups to pharma, clinical practice to academia.

Stanford most recently served as President and Head of Research and Development of Alpine Immune Sciences (Nasdaq: ALPN), a biopharmaceutical company focused on the application of directed evolution for the development of novel protein-based therapeutics for autoimmune and inflammatory diseases. Under his management, Alpine discovered and introduced into the clinic multiple drug candidates, including povetacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy and other autoimmune diseases, prompting its acquisition by Vertex Pharmaceuticals.

Previously, Stanford held various leadership and management positions in multiple biotech, pharma and academic settings, including Stemcentrx (until its acquisition by AbbVie), Seagen, Roche, Benaroya Research Institute, and Washington University in St. Louis.

Stanford received a B.A. and B.S. in Music and Biological Sciences from Stanford University, as well as an M.D. and Ph.D. in Biology from Yale University. He conducted his residency in internal medicine at the University of Pennsylvania and was a Clinical and Research Fellow in rheumatology at Brigham & Women’s Hospital. Stanford continues to be a practicing rheumatologist.